Archive

Category: ACG 2021

Guardant Health Presents Results of LUNAR-2 Blood Test for the Treatment of Early-Stage Colorectal Cancer at ACG 2021

Shots: The study evaluates the LUNAR-2 test in 699 patients with early-stage Stage 1, 2, or 3 CRC which showed a 96% overall sensitivity & 94% specificity. The test is designed to detect early-stage cancer in screen-eligible asymptomatic adults through a blood sample In an additional analysis, the test showed 93% overall sensitivity in patients […]

ViewPoints Interview: Takeda’s Nirav Desai Shares Insight on Data of TAK-721 Presented at ACG 2021

In an interview with Nirav Desai, Global Clinical Development Lead at Takeda shared his views on Tak-721 presented at ACG 2021 and its implications for patients and HCPs. The presentation includes post hoc analyses from a 12-week, randomized, double-blind, placebo-controlled Phase 3 clinical trial that investigated the safety and efficacy of BOS in patients with EoE 11 to 55 […]